Back to top
more

Minerva Neurosciences (NERV)

(Delayed Data from NSDQ)

$2.52 USD

2.52
2,186

-0.05 (-1.90%)

Updated May 17, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NERV

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Minerva Neurosciences, Inc [NERV]

Reports for Purchase

Showing records 21 - 40 ( 42 total )

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 21

01/20/2021

Company Report

Pages: 4

Monetization of Seltorexant Should Allow Minerva to Capture Roluperidone’s Full Potential; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 22

12/02/2020

Daily Note

Pages: 4

FDA Likes Roluperidone, But Has Issues With the Current Data Package; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 23

11/03/2020

Company Report

Pages: 5

FDA Meeting Expected to Provide Clarity on Roluperidone’s Path Forward; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 24

09/09/2020

Daily Note

Pages: 3

Minerva Schedules FDA Meeting Regarding Roluperidone; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 25

08/04/2020

Company Report

Pages: 5

Upcoming FDA Meeting Should Provide Visibility for Roluperidone’s Path; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 26

07/02/2020

Company Report

Pages: 4

Minerva Opts out of Seltorexant Agreement With Janssen to Focus on Roluperidone

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 27

06/08/2020

Company Report

Pages: 6

We Still Like Roluperidone After Another Look at the Data; Reiterate Buy, Target to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 28

05/29/2020

Daily Note

Pages: 4

Quick Thoughts After Roluperidone Misses Primary Endpoint in Phase 3

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 29

05/05/2020

Company Report

Pages: 5

No News Is Good News as Roluperidone Phase 3 Readout Rapidly Approaches; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 30

04/17/2020

Industry Report

Pages: 16

Don''t Sleep on New Mechanisms for MDD: A Look at GABA Modulation and Orexin-2 Antagonists

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 31

04/01/2020

Daily Note

Pages: 4

KOLs Highlight Roluperidone as Potential Game Changer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 32

03/30/2020

Daily Note

Pages: 94

Market Shudders But We See Names to Outperform.

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 33

03/10/2020

Company Report

Pages: 5

Roluperidone Readout on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 34

03/09/2020

Daily Note

Pages: 4

KOLs Highlight Broader Opportunity for Roluperidone; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 35

12/19/2019

Company Report

Pages: 4

MIN-117 Fails Short, But It Wasn''t Central to Our Thesis; Tweak Target Down to $20, Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 36

11/20/2019

Industry Report

Pages: 7

Perspectives from KOL Dinner on Major Depressive Disorder

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 37

11/05/2019

Company Report

Pages: 6

Key Catalysts Upcoming for a Pipeline With Differentiated Assets; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 38

10/02/2019

Company Report

Pages: 4

Missing the Forest for the Trees as Seltorexant Shines Again; Reiterate Buy and $22 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 39

08/06/2019

Company Report

Pages: 6

Plentiful Catalysts Into Year-End Make it Hard to Ignore; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 40

06/25/2019

Company Report

Pages: 4

Another Win for MIN-202 Differentiates Profile Further

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party